Mucin 5AC (MUC5AC) Mouse Monoclonal Antibody [Clone ID: MRQ-19]

CAT#: TA327703

Mouse Monoclonal MUC 5AC Antibody

Product Images

Immunohistochemistry staining of Paraffin Stomach tissue by MUC 5AC antibody (dilution: 1:100 - 1:500; visualization of staining: Cytoplasmic)

Specifications

Product Data

• Clone Name: MRQ-19
• Applications: IHC
• Recommended Dilution: IHC: 1:100 - 1:500
• Reactivities: Human
• Host: Mouse
• Isotype: IgG1
• Clonality: Monoclonal
• Formulation: This antibody is supplied as cell culture supernatant diluted in tris buffered saline, pH 7.3-7.7, with 1% BSA and <0.1% sodium azide.
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: mucin 5AC, oligomeric mucus/gel-forming
• Database Link:
  NP_059981
  Entrez Gene 4586 Human
  UniProt ID P98088
• Synonyms: gastric; gastric mucin; gel-forming; MUC5; mucin 5; mucin 5AC; oligomeric mucus; subtypes A and C; tracheobronchial; tracheobronchial mucin
• Note: Mucins are high molecular weight glycoproteins which constitute the major component of the mucus layer that protects the gastric epithelium. The heterogeneous pattern of mucin expression, including the expression of the intestinal mucin MUC2, may provide new insights into the differentiation pathways of gastric carcinoma. Pinto-de-Sousa et al. have shown, in a comprehensive study of gastric carcinomas evaluated for expression of several mucins (MUC1, MUC2, MUC5AC and MUC6), that: (1) mucin expression is associated with tumor type (MUC5AC with diffuse and infiltrative carcinomas and MUC2 with mucinous carcinomas) but not with the clinico-biological behavior of the tumors; and (2) mucin expression is associated with tumor location (MUC5AC with antrum carcinomas and MUC2 with cardia carcinomas), indirectly reflecting differences in tumor differentiation according to tumor location. The following generalities apply to the patterns of MUC5AC expression: Preferentially expressed in the normal stomach and respiratory tract; esophageal carcinomas – 67%, gastric carcinomas – 58%, colonic carcinomas – 6%-25%, pancreatic ductal carcinomas – 73%, cholangiocarcinomas – 45%, endocervical adenocarcinomas – 70%, endometrial adenocarcinomas – 22%, and lung adenocarcinomas – 14%.

Reference Data

• Protein Families: Druggable Genome